Home › NCT07566286

Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region

A Prospective, Multicenter Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

Who can join

Ages 22 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
2. Intent to receive treatment for augmentation and correction of retrusion in the chin region.

Exclusion Criteria:

1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.
2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.
3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.
5. Any previous aesthetic procedures or implants.
6. Presence of any disease or lesions near or on the area to be treated.

About the study

The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.

What is being tested

• Restylane Lyft with Lidocaine (device)

Sponsor: Galderma R&D · Participants: 100 · Started: Jun 3, 2026

Contact the study team

• Clinical Project Manager · Phone: 817-961-5000

Official record on ClinicalTrials.gov — NCT07566286

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.